Abstract
Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients. This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-A13.
Keywords: Rational drug design, tyrosine kinases, BTK, cancer, thromboembolism
Anti-Cancer Agents in Medicinal Chemistry
Title: Brutons Tyrosine Kinase as a New Therapeutic Target
Volume: 7 Issue: 6
Author(s): Fatih M. Uckun, Heather E. Tibbles and Alexei O. Vassilev
Affiliation:
Keywords: Rational drug design, tyrosine kinases, BTK, cancer, thromboembolism
Abstract: Targeting Brutons tyrosine kinase (BTK) with a small molecule inhibitor may be useful in treatment of BTK-expressing malignancies because of the anti-apoptotic function of BTK in cancer cells. Furthermore, BTK inhibitors also exhibit anti-thrombotic properties that may be desirable in the context of the increased risk of thromboembolic complications in cancer patients. This review will focus on the role of BTK in drug resistance in cancer, thromboembolism, and various pathologic immune responses, such as graft versus host disease. The therapeutic potential of targeting BTK is illustrated by discussion of the biologic activity profile of the rationally designed BTK inhibitor LFM-A13.
Export Options
About this article
Cite this article as:
Uckun M. Fatih, Tibbles E. Heather and Vassilev O. Alexei, Brutons Tyrosine Kinase as a New Therapeutic Target, Anti-Cancer Agents in Medicinal Chemistry 2007; 7 (6) . https://dx.doi.org/10.2174/187152007784111331
DOI https://dx.doi.org/10.2174/187152007784111331 |
Print ISSN 1871-5206 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5992 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Tissue Factor/Factor FVII Complex Inhibitors in Cardiovascular Disease. Are Things Going Well?
Current Cardiology Reviews Editorial [Hot Topic: Therapeutic Angiogenesis and Regeneration in Cardiovascular Diseases (Executive Editor: Masafumi Takahashi)]
Current Pharmaceutical Design Microcirculation of the Diabetic Foot
Current Pharmaceutical Design Heart Failure in Sub-Saharan Africa
Current Cardiology Reviews Microglial Activation as a Compelling Target for Treating Acute Traumatic Brain Injury
Current Medicinal Chemistry Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Modulation of Cardiovascular Function by Adipokines
Cardiovascular & Hematological Disorders-Drug Targets Managing Comorbidity in COPD: A Difficult Task
Current Drug Targets The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry Targets Involved in Cardioprotection by the Non-Anesthetic Noble Gas Helium
Current Drug Targets Targeting JAK/STAT Signaling Pathway in Inflammatory Diseases
Current Signal Transduction Therapy Immunologic Modulations to Enhance Post-Stroke Recovery
Current Immunology Reviews (Discontinued) Alternative Pharmacological Interventions that Limit Myocardial Infarction
Current Medicinal Chemistry Hydrogen Sulfide as a New Endogenous Gaseous Transmitter in the Cardiovascular System
Current Vascular Pharmacology Radiopharmaceuticals in Tumor Hypoxia Imaging: A Review Focused on Medicinal Chemistry Aspects
Anti-Cancer Agents in Medicinal Chemistry Mitochondrial Dynamics: An Emerging Paradigm in Ischemia-Reperfusion Injury
Current Pharmaceutical Design Hydroxysafflor Yellow A Attenuates Renal Ischemia- Reperfusion Injury in a Rat Model
Letters in Drug Design & Discovery Regular Physical Activity and Vascular Aging
Current Pharmaceutical Design Can the Electrophysiological Action of Rosiglitazone Explain its Cardiac Side Effects?
Current Medicinal Chemistry Insights into the Pathogenesis and Intervention of Atherosclerosis
Vascular Disease Prevention (Discontinued)